Dr. Goy on Future Agents Against Lymphoma

Partner | Cancer Centers | <b>John Theurer Cancer Center</b>

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.

Goy says there are many small molecule agents that will continue to change the landscape of the treatment of lymphoma but research into CAR technology in large-cell lymphoma is striking. A trial of this technology has shown that 8 out of 9 large-cell lymphoma patients were primary refractory or refractory to chemotherapy responded to treatment.

Manipulating the immune system and building up on PD-1 are critical to the future of lymphoma, Goy says.